Compare · NNNN vs QDEL
NNNN vs QDEL
Side-by-side comparison of Anbio Biotechnology (NNNN) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NNNN and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $2.37B, about 2.8x QDEL ($843.5M).
- QDEL has been more active in the news (16 items in the past 4 weeks vs 2 for NNNN).
- QDEL has more recent analyst coverage (19 ratings vs 0 for NNNN).
- Company
- Anbio Biotechnology
- QuidelOrtho Corporation
- Price
- $16.73-3.35%
- $12.38-9.51%
- Market cap
- $2.37B
- $843.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 2
- 16
- Recent ratings
- 0
- 19
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest NNNN
- SEC Form 3 filed by new insider Zhang Michael W.C
- SEC Form 3 filed by new insider Hsu David H
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
Latest QDEL
- SEC Form 8-K filed by QuidelOrtho Corporation
- Director Widder Kenneth J was granted 1,183 shares, increasing direct ownership by 3% to 45,073 units (SEC Form 4)
- Director Polan Mary Lake Ph D was granted 973 shares, increasing direct ownership by 5% to 20,442 units (SEC Form 4)
- Director Buechler Kenneth F was granted 2,156 shares, increasing direct ownership by 2% to 110,906 units (SEC Form 4)
- Director Michael Edward L. was granted 1,252 shares, increasing direct ownership by 4% to 29,433 units (SEC Form 4)
- Director Strobeck Matthew was granted 6,829 shares, increasing direct ownership by 25% to 34,604 units (SEC Form 4)
- Director Widder Kenneth J was granted 6,829 shares, increasing direct ownership by 18% to 43,890 units (SEC Form 4)
- Director Polan Mary Lake Ph D was granted 6,829 shares, increasing direct ownership by 54% to 19,469 units (SEC Form 4)
- Director Buechler Kenneth F was granted 6,829 shares, increasing direct ownership by 7% to 108,750 units (SEC Form 4)
- Director Chiminski John R was granted 6,829 shares, increasing direct ownership by 271% to 9,352 units (SEC Form 4)